9 August 2019 - Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks.
Gilead Sciences announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.
Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir with the demonstrated safety and efficacy profile of the Descovy (emtricitabine 200 mg/tenofovir alafenamide 25 mg; dual nucleoside reverse transcriptase inhibitor backbone and is the smallest INSTI-based triple-therapy STR available.
In China, Biktarvy is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.